Korean Journal of Clinical Pharmacy

Table. 5. Table 5

Baseline characteristics of users of rivaroxaban vs. dabigatran

Characteristics, %	Before PS matched			1:1 PS matched

	New Rivaroxaban (n=1,079)	Dabigatran (n=721)	p-value	New rivaroxaban (n=721)	Matched dabigatran (n=721)	p-value
Age, years	75.86±6.31	75.23±6.06	0.03	75.69±6.31	75.23±6.06	0.16
Age ≥ 75 years	55.61	52.57	0.21	55.20	52.57	0.34
Female	52.64	50.35	0.36	52.70	50.35	0.40
Comorbidity
Hypertension	79.43	78.92	0.81	79.75	78.92	0.75
Diabetes	18.44	17.06	0.49	18.31	17.06	0.58
Myocardial infarction	1.48	0.55	0.07	1.53	0.55	0.12
Heart Failure	43.28	35.09	<0.01	44.24	35.09	<0.01
Ischemic stroke/Transient ischemic attack	0.28	0.42	0.69	0.42	0.42	1.00
Peripheral vascular disease	0.74	1.25	0.32	0.55	1.25	0.27
Dementia	0.46	0.28	0.71	0.28	0.28	1.00
Renal Disease	1.30	1.53	0.69	1.11	1.53	0.65
Chronic pulmonary disease	6.58	8.04	0.26	6.52	8.04	0.31
Liver disease	5.56	5.27	0.83	5.96	5.27	0.65
Cancer	1.20	0.69	0.34	1.25	0.69	0.42
depression	1.85	2.36	0.50	1.25	2.36	0.17
Hematological disorders (Coagulopathy, anemia)	2.87	3.61	0.41	2.64	3.61	0.36
Alcoholism	0.19	0.55	0.23	0.28	0.55	0.69
GI bleeding	0.46	0.69	0.53	0.42	0.69	0.73
Other bleeding	0.74	0.69	1.00	0.69	0.69	1.00
CHA₂DS₂-VASC score ≥ 2	98.61	98.06	0.45	99.03	98.06	0.19
Medications,%
Digoxin	19.74	19.28	0.86	19.69	19.28	0.89
Clopidogrel	4.91	4.30	0.57	5.41	4.30	0.39
Antiplatelets	8.53	8.04	0.73	9.15	8.04	0.51
ACEI/ARB	37.81	36.48	0.58	37.31	36.48	0.79
β-blockers	47.08	47.30	0.96	47.99	47.30	0.83
Ca channel blockers	9.36	9.43	1.00	9.02	9.43	0.86
Anti-arrhythmias	18.44	24.83	<0.01	19.28	24.83	0.01
Statins	30.58	32.45	0.41	31.76	32.45	0.82
Diabetes medication	8.99	10.68	0.26	9.02	10.68	0.33

PS, propensity score